CNBC Closing Bell

2026-08-04 · Hosted by Scott Wapner, Melissa Lee, Michael Santoli · CNBC

Executive Summary

Stocks rallied hard to start the week, with the Dow gaining roughly 700 points to a record close, the S&P 500 up 1.5%, and the Nasdaq up more than 2%. A drop in oil prices and easing Middle East tensions helped clear the way, while Amazon and Microsoft extended their post-earnings surge, both up more than 20% over five trading sessions and adding a combined $1.8 trillion in market cap since Wednesday's close. Palantir, ON Semiconductor, and Snap all posted strong earnings beats after the bell, sending their shares sharply higher in extended trading.

Key Stories & Changes

1. Dow, S&P, Nasdaq Rally on Big Tech Strength

  • Dow gained ~700 points to a record close; S&P 500 rose 1.5%, narrowly missing a record; Nasdaq rose over 2%

  • Amazon and Microsoft up more than 20% in five sessions, adding $1.8 trillion in combined market cap since Wednesday

  • Chips were mixed (weakness tied to Korea/China headlines) while software and mega-cap tech broadly outperformed

  • Apple was the lone Mag 7 decliner, still weighed down by last Thursday's disappointing earnings

  • Momentum names Coherent and other optical chip stocks also led S&P gains

2. Earnings Beats: Palantir, ON Semiconductor, Snap

  • PLTR: Palantir — +10%+ after hours — Q2 adjusted EPS of $0.41 vs. $0.35 estimate; revenue of $1.94B beat estimates; US commercial revenue grew nearly 150% YoY; raised full-year guidance

  • ON: ON Semiconductor — +1.5% — Adjusted EPS $0.74 beat; revenue $1.6B roughly in line; guided Q3 EPS $0.81-$0.93 on revenue $1.65-1.75B, above estimates; AI data center revenue seen more than doubling in 2026

  • SNAP: Snap — +9% (up to 8.5% intraday) — Revenue $1.6B beat $1.54B estimate; adjusted EBITDA $250M vs. $192M estimate; DAUs of 493M beat expectations; Q3 revenue guide of $1.7-1.74B above consensus

3. Palantir CEO Doubles Down on Anthropic/OpenAI Criticism

  • CEO Alex Karp criticized frontier AI labs, saying "we have people trying to drug addict us to a future they believe they control"

  • Karp said organizations are "awakening to the risks" of ceding control to language-model creators, tying this to a broader AI sovereignty movement

  • Commercial revenue strength (~150% YoY growth) is directly benefiting from this open-source/sovereignty pivot narrative, per Bloomberg's coverage

  • Analyst Louis de Palma (William Blair) noted Palantir's total deal value in U.S. commercial accelerated to 158% from 47% last quarter

4. Yen Intervention and Bond Market Moves

  • The U.S. intervened to support the yen over the weekend, the first coordinated intervention since 1998; dollar-yen hovering just below 157

  • 10-year yield fell about 5 basis points; Friday's close was the highest since January 2025

  • Rick Santelli noted the dollar has moved from 40-year highs against the yen in early July to three-month lows

  • Rate strategists caution the intervention's effects are unlikely to be lasting without accompanying rate action from both central banks

5. Oil Slides on Iran De-escalation

  • Oil fell 5% after President Trump called off planned attacks on Iran; mixed messaging on Strait of Hormuz reopening timeline

  • Data from Kepler showed still-constrained shipping traffic (nine ships crossing) despite claims of an open strait

  • Trump separately criticized Exxon and Chevron for "making too much money," calling for lower prices

  • Analysts flagged potential for tech weakness to free up capital rotating into energy, still under 4% of the S&P

6. AstraZeneca/Bristol Myers Mega-Merger Speculation

  • Financial Times reported talks of a potential $400 billion merger between AstraZeneca and Bristol Myers Squibb

  • AstraZeneca shares fell about 7% on the news; Goldman's Assad Hader noted investor concern the deal signals reduced confidence in AstraZeneca's own pipeline following a recent trial setback

  • Bristol Myers would gain greater U.S. revenue exposure (currently ~40% of total revenue, below peer average)

  • Possible contingent value rights (CVR) structure discussed, drawing comparison to Bristol's 2019 Celgene acquisition

7. Housing Market Pressure from Rising Rates

  • 30-year fixed mortgage rate at 6.82%, highest in over a year, per Mortgage News Daily

  • Refinance demand fell 10% week-over-week; purchase demand fell 4%

  • Homebuilder ETF (ITB) underperformed the S&P 500 for all of July for the first time since 2014

  • A buyer of a $450,000 home now pays roughly $200/month more than at the end of February

8. China AI/Chip Competition Intensifies

  • Alibaba unveiled Qwen 3.8 Max, its most powerful model yet, sending shares higher

  • China's CXMT reportedly in talks for local government backing to build another memory fab in Beijing

  • Hugging Face CEO Clem Delangue said China is "clearly dominating" open models due to more open science practices

  • Casey Newton noted the best Chinese models are estimated to be three to seven months behind the frontier, but that gap may be narrowing to a level that still matters commercially

1. Hyperscaler Capital Expenditure Is Being Rewarded, Not Punished

Following a period of investor anxiety about AI infrastructure spending, Microsoft and Amazon's earnings showed cloud backlog growth to **$1.7-1.8 trillion** and clear monetization signals, triggering explosive share gains. Guest Anastasia Amoroso framed this as the market finally seeing return on investment (ROI) materialize from prior capital expenditure (CapEx), rather than continued blind faith in future promises.

2. Rotation From AI Concentration Into Broader Winners

Money moved beyond the largest AI-pure-play names into adjacent beneficiaries: transports, retail (Macy's, Target), refiners, and industrial suppliers like Ferguson, which benefits from data center buildout demand for pipes and HVAC. This signals the market broadening its AI-adjacent thesis beyond mega-cap tech.

3. Open-Source and Chinese AI Competition as a Long-Term Overhang

Multiple guests flagged that competition from Chinese open-source models (Alibaba's Qwen, DeepSeek, Kimi) and Chinese chipmakers (CXMT) could eventually commoditize AI models and compress semiconductor pricing power, even if near-term demand remains robust.

4. Pharma M&A Wave Amid Patent Cliffs

The AstraZeneca-Bristol Myers speculation, alongside ongoing catalysts at Lilly, Merck, and Pfizer, points to consolidation pressure across large pharma as companies race to offset looming patent expirations and pricing pressure tied to the MFN (most-favored-nation) drug pricing framework.

5. Currency Intervention as a Coordinated Policy Signal

The first joint U.S.-Japan currency intervention since 1998 suggests policymakers view yen weakness as a systemic concern, not just a Japan-specific issue, with implications for carry trades and global bond market volatility. ---

Sentiment Analysis

Overall Market Sentiment: Bullish, Broadening Rally

The tone was decisively positive, with the rally seen as extending beyond mega-cap tech into industrials, retail, and energy, though some guests flagged competitive and financing risks on the horizon.

Risk Factors Highlighted

SpaceX lock-up expiration: 911 million shares become eligible to sell Thursday, with up to 4 billion shares unlocking through January 2027 per Morgan Stanley.

AI financing overhang: Free cash flow is being consumed rapidly by hyperscalers; debt markets are increasingly relied upon to fund CapEx.

Chinese chip and model competition: CXMT's potential new fab and Alibaba's Qwen 3.8 Max threaten U.S. semiconductor and AI model pricing power.

Currency intervention limits: Rick Santelli and Rick strategists note interventions historically don't hold long-term without matching rate policy.

Housing market deterioration: Mortgage rates nearing the psychologically important 7% level could further dent builder margins and consumer demand.

Geopolitical uncertainty in the Middle East: Mixed signals on Strait of Hormuz status and Iran talks add volatility risk to oil markets.

Pharma pipeline setbacks: AstraZeneca's recent trial failure and merger speculation reflect broader uncertainty in large pharma pipeline execution.

This episode was covered in today's [The Market Signal — 2026-08-04](https://marketsignal.beehiiv.com/p/the-market-signal-2026-08-04), a cross-source synthesis of multiple podcast reports.

Keep Reading